News | October 27, 2025
Zydus receives approval from Health Canada for Mesalamine suppositories
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Subscribe To Our Newsletter & Stay Updated
